Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?

dc.contributor.authorTuon F.F.
dc.contributor.authorRymsza A.M.
dc.contributor.authorPenteado-Filho S.R.
dc.contributor.authorPilonetto M.
dc.contributor.authorArend L.N.
dc.contributor.authorLevin A.S.
dc.date.accessioned2024-03-13T01:11:40Z
dc.date.available2024-03-13T01:11:40Z
dc.date.issued2011
dc.description.firstpage246
dc.description.issuenumber3
dc.description.lastpage249
dc.description.volume62
dc.identifier.doi10.1016/j.jinf.2011.01.005
dc.identifier.issn0163-4453
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/37009
dc.relation.ispartofJournal of Infection
dc.rightsAcesso Restrito
dc.titleShould polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
dc.typeCarta ao editor
local.scopus.citations12
local.scopus.eid2-s2.0-79952196433
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79952196433&origin=inward
Arquivos